Kelonia Therapeutics, Inc.

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
BCMAGene therapy / editing
Multiple Myeloma

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 June 2026PresentationKLN-1010Phase 1 inMMyCAR (NCT07075185) interim data at ASCO 2026: 100% overall response rate
April 2026Licensing dealKLN-1010Eli Lilly agrees to acquire Kelonia Therapeutics (pending close)
Eli Lilly · Source ↗

Financial reports

No financial reports recorded.